This is a global, multi-center pre-screening study. This study does not involve any investigational medication, but it will assess participants’ potential suitability for a Roche interventional Alzheimer’s disease (AD) study based on cognitive testing and a blood test detecting plasma levels of a protein related to AD called pTau217. This pre-screening process is to support earlier and easier detection of people with early symptomatic AD. Study duration is expected to be a couple of hours over 1 or 2 days.
The purpose of the TRAVELLER study is to identify people who are best suited to participate in one of Roche’s Alzheimer’s disease clinical studies.
This study also aims to engage with diverse communities to ensure we include all people living with Alzheimer’s disease, regardless of race, ethnicity, physical or mental ability, religion, and education or income level.
The participants in this study must be between the ages of 50-90 and have had concerns about their memory or been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease within the last year .
Interested participants can contact the Memory and Aging Program Outreach Team at (401) 455-6402 or by sending an email to memory@butler.org to discuss additional eligibility criteria.